AT LEAST 14 DAYS SHOULD ELAPSE BETWEEN DISCONTINUATION OF A MAOI AND INITIATION OF THERAPY WITH VORTIOXETINE TO AVOID THE RISK OF SEROTONIN SYNDROME. REDUCE THE DOSE OF VORTIOXETINE BY HALF WHEN PATIENTS ARE RECEIVING A CYP2D6 STRONG INHIBITOR E.G., BUPROPION, FLUOXETINE, PAROXETINE, OR QUINIDINE. CONSIDER INCREASING THE DOSE OF VORTIOXETINE WHEN A STRONG CYP INDUCER (E.G., RIFAMPIN, CARBAMAZEPINE, OR PHENYTOIN) IS COADMINISTERED FOR GREATER THAN 14 DAYS. THE MAXIMUM RECOMMENDED DOSE SHOULD NOT EXCEED THREE TIMES THE ORIGINAL DOSE.